Skip to main content
TipRanks
Go Ultimate75% OFF

Natera (NTRA) Stock Price & Analysis

1,379 Followers

NTRA Stock Chart & Stats

$289.92$0.42(0.15%)
At close: 4:00 PM EST
$300$350$400Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$288.20 - $307.19
52-Week Range
$181.00 - $437.41
Previous Close
$289.50
Volume
N/A
Average Volume (3M)
1.96M
Market Cap
$42.04B
Enterprise Value
$58.69B
Total Cash (Recent Filing)
$1.10B
Total Debt (Recent Filing)
$238.84M
Price to Earnings (P/E)
―
Beta
1.09
Next Earnings
Mar 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth

The higher revenue outlook, supported by continued volume growth and steady ASPs, indicates broadening clinical adoption and stronger commercial execution. Sustained growth across oncology, women’s health, and organ health can expand operating leverage and reinforce Natera’s market position over the next several quarters.

Improving Margins And Cash Generation

Positive operating cash flow and materially higher gross margins show that scale is improving Natera’s underlying economics. Although profitability is not yet established, sustained cash generation provides resources to fund trials, commercial expansion, and technology investment without relying solely on external capital.

MRD Adoption And Clinical Validation

Rapid MRD volume growth, repeat testing, and expanding clinical evidence support Signatera’s potential as a durable monitoring platform rather than a single-use test. Greater physician confidence and adoption across indications can strengthen recurring utilization, reimbursement discussions, and long-term pricing power.

Bears Say

Profitability Remains Negative

Natera has not yet converted strong revenue growth and improved gross margins into sustainable operating profitability. Continued losses leave execution dependent on maintaining high growth and disciplined spending, while any slowdown could delay the point at which the business consistently funds expansion from earnings.

Elevated Investment And Expense Growth

Higher spending on MRD trials, early detection, pharma services, data initiatives, and commercial programs may support future growth but increases the near-term burden on earnings and cash conversion. If these investments take longer to monetize, margin expansion and the path to profitability could be delayed.

Reimbursement Execution Uncertainty

Broader reimbursement is important to converting clinical evidence into durable test volume and collections. Uncertain MolDX decisions could delay coverage expansion, constrain adoption in additional indications, and make revenue timing less predictable while Natera continues funding evidence generation and regulatory work.

Natera News

NTRA FAQ

What was Natera’s price range in the past 12 months?
Natera lowest stock price was $181.00 and its highest was $437.41 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is $42.04B.
When is Natera’s upcoming earnings report date?
Natera’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 104 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Nov 05, 2026. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.281 by -$0.139.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.16.
How many shares outstanding does Natera have?
Natera has 145,004,520 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.281. Following the earnings report the stock price went down -14.595%.
Which hedge fund is a major shareholder of Natera?
Hedge funds hold Natera shares: the largest hedge-fund position in Natera is 72,328,169 shares, and hedge funds decreased their holdings by 1.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology